Arkhangelsk Clinical Oncological Dispensary

Arkhangelsk 163045

0 studies enrolling now · 7 studies all time

What they study most

Advanced Cancer, Biliary Tract Cancer, Complete Response, Epithelial Ovarian Cancer, FIGO Stage III-IV, Fallopian Tube Cancer, HER2 Exon 20 Mutation, Hepatocellular Carcinoma, Liver Cancer, Locally Advanced Pancreatic Cancer, Metastatic Cancer, Metastatic Non-small Cell Lung Cancer

Studies at this site

• A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation — Running, not enrolling
• A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer — Running, not enrolling
• A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) — Completed
• Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy — Completed
• A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy — Running, not enrolling
• ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients — Completed
• EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX — Completed